Recurrent Endometrial Carcinoma (DBCOND0028796)

Identifiers

Synonyms
Endometrial carcinoma recurrent / Carcinoma endometrial recurrent / Endometrial Carcinoma, Recurrent / Endometrial cancer recurrent / Cancer of endometrium recurrent / Ca endometrium recurrent

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Megestrol acetate
A progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT03015129
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancertreatment2completed
NCT05112601
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinomatreatment2recruiting
NCT05554328
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trialtreatment2recruiting
NCT05564377
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trialscreening2recruiting
NCT05691504
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancerstreatment1recruiting
NCT06518564
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer (Prior IO)treatment2not_yet_recruiting
NCT04469764
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancertreatment2recruiting
NCT00301964
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancertreatment2completed
NCT01198184
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumorstreatment1completed
NCT03586661
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancertreatment1active_not_recruiting
NCT04781088
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2active_not_recruiting
NCT03968406
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancerstreatment1recruiting
NCT00462826
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancertreatment2completed
NCT04906382
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancertreatment0terminated
NCT01652794
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancertreatment1completed
NCT01764789
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast CancerNo drug interventionssupportive_careNot Availablecompleted
NCT00025467
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancertreatment2completed
NCT02093546
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290No drug interventionsNot AvailableNot Availablecompleted
NCT00031681
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)treatment1completed
NCT01689714
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial CarcinomaNo drug interventionsother2completed
NCT05192850
Endometrial Cancer Recurrence in Patients Taking MetforminNot AvailableNot Availableactive_not_recruiting
NCT06502743
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancertreatment2not_yet_recruiting
NCT00095979
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancertreatment2completed
NCT00096447
Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancertreatment2completed
NCT03924245
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancerstreatment1terminated
NCT01079832
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological MalignanciesNo drug interventionstreatment2completed
NCT03508570
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosistreatment1active_not_recruiting
NCT03367741
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancertreatment2active_not_recruiting
NCT05997017
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancertreatment2recruiting
NCT03120624
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancertreatment1active_not_recruiting
NCT01943058
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancertreatment2withdrawn
NCT01155258
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumorstreatment1completed
NCT00028535
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumorstreatment1completed
NCT00004074
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neutreatment1completed
NCT00072176
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancertreatment2completed
NCT05523440
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutationtreatment2recruiting
NCT03914612
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancertreatment3active_not_recruiting
NCT05603910
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinomatreatment1recruiting
NCT00723255
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancertreatment2completed
NCT00408655
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumorstreatment1completed
NCT03008408
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinomatreatment2active_not_recruiting